{"id":72497,"date":"2026-08-14T12:04:11","date_gmt":"2026-08-14T04:04:11","guid":{"rendered":"https:\/\/flcube.com\/?p=72497"},"modified":"2026-08-14T12:04:12","modified_gmt":"2026-08-14T04:04:12","slug":"celgenyx-secures-fda-ind-clearance-for-cg101-off-the-shelf-ipsc-derived-cell-therapy-in-acute-myeloid-leukemia-multicenter-phase-i-study-to-begin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72497","title":{"rendered":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Celgenyx, Inc.<\/strong> announced today that <strong>CG101<\/strong>, its self\u2011developed <strong>off\u2011the\u2011shelf immune cell therapy<\/strong> product for the treatment of <strong>acute myeloid leukemia (AML)<\/strong>, has officially received <strong>Investigational New Drug (IND) clearance<\/strong> from the <strong>US FDA<\/strong> to proceed with a <strong>multicenter Phase I clinical study<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>US Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Clearance Type<\/strong><\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td><strong>CG101<\/strong> (self\u2011developed by Celgenyx, Inc.)<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td>Off\u2011the\u2011shelf immune cell therapy, iPSC\u2011derived<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Acute myeloid leukemia (AML)<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Multicenter Phase I clinical study<\/td><\/tr><tr><td><strong>IND Clearance Date<\/strong><\/td><td>14 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> <strong>Off\u2011the\u2011shelf immune cell therapy<\/strong> derived from <strong>human induced pluripotent stem cells (iPSCs)<\/strong> \u2014 enabling standardized, ready\u2011to\u2011use dosing without patient\u2011specific manufacturing.<\/li>\n\n\n\n<li><strong>Engineering:<\/strong> Through <strong>precise gene editing<\/strong>, CG101 is engineered with:<\/li>\n\n\n\n<li><strong>Enhanced immunological activity<\/strong><\/li>\n\n\n\n<li><strong>Targeted chemotactic migration<\/strong><\/li>\n\n\n\n<li><strong>Increased infiltration and persistence in tumor tissues<\/strong><\/li>\n\n\n\n<li>The ability to <strong>remodel the immunosuppressive microenvironment<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Outcome:<\/strong> The combined engineering features demonstrate <strong>potent anti\u2011tumor activity and sustained efficacy<\/strong> in the AML setting.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Off\u2011the\u2011Shelf Advantage:<\/strong> Unlike autologous therapies, <strong>off\u2011the\u2011shelf<\/strong> products can be manufactured at scale and delivered on demand \u2014 addressing cost, turnaround time, and accessibility constraints that limit patient\u2011specific cell therapies.<\/li>\n\n\n\n<li><strong>iPSC Platform Validation:<\/strong> The IND clearance validates <strong>Celgenyx&#8217;s<\/strong> iPSC derivation and gene\u2011editing capabilities, with potential applicability beyond AML to other hematologic malignancies and solid tumors.<\/li>\n\n\n\n<li><strong>Microenvironment Remodeling:<\/strong> CG101&#8217;s ability to remodel the <strong>immunosuppressive microenvironment<\/strong> is a differentiated trait that could extend efficacy into tumor types where conventional cell therapies struggle.<\/li>\n\n\n\n<li><strong>Clinical Inflection Point:<\/strong> The multicenter <strong>Phase I study<\/strong> will generate the first human safety and preliminary efficacy data for CG101 \u2014 the key value inflection for the program.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development of CG101, the conduct of the multicenter Phase I study, and potential applications of Celgenyx&#8217;s iPSC platform. Actual results may differ due to risks including clinical outcomes, regulatory requirements, manufacturing scale\u2011up, and competitive dynamics in cell therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[3490,77,62],"class_list":["post-72497","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-celgenyx-gene-technology","tag-cell-therapy","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72497\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin\" \/>\n<meta property=\"og:description\" content=\"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72497\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-14T04:04:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-14T04:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin\",\"datePublished\":\"2026-08-14T04:04:11+00:00\",\"dateModified\":\"2026-08-14T04:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Celgenyx Gene Technology\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72497#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72497\",\"name\":\"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-14T04:04:11+00:00\",\"dateModified\":\"2026-08-14T04:04:12+00:00\",\"description\":\"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72497\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72497#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin - Insight, China&#039;s Pharmaceutical Industry","description":"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72497","og_locale":"en_US","og_type":"article","og_title":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin","og_description":"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.","og_url":"https:\/\/flcube.com\/?p=72497","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-14T04:04:11+00:00","article_modified_time":"2026-08-14T04:04:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72497#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72497"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin","datePublished":"2026-08-14T04:04:11+00:00","dateModified":"2026-08-14T04:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72497"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Celgenyx Gene Technology","Cell-therapy","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72497#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72497","url":"https:\/\/flcube.com\/?p=72497","name":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-14T04:04:11+00:00","dateModified":"2026-08-14T04:04:12+00:00","description":"Celgenyx, Inc. announced today that CG101, its self\u2011developed off\u2011the\u2011shelf immune cell therapy product for the treatment of acute myeloid leukemia (AML), has officially received Investigational New Drug (IND) clearance from the US FDA to proceed with a multicenter Phase I clinical study.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72497#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72497"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72497#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Celgenyx Secures FDA IND Clearance for CG101 Off\u2011the\u2011Shelf iPSC\u2011Derived Cell Therapy in Acute Myeloid Leukemia \u2013 Multicenter Phase I Study to Begin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72497"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72497\/revisions"}],"predecessor-version":[{"id":72498,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72497\/revisions\/72498"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}